First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience.

ABSTRACT:

Introduction

Clinical trial data has shown pazopanib to be non-inferior in overall survival (OS) compared to sunitinib as first-line treatment for metastatic renal cell carcinoma (mRCC). The purpose of this study was to evaluate outcomes and compare dose-modifying toxicities of mRCC patients treated with suntinib or pazopanib in the real-world setting.

Methods

Data were collected on mRCC patients using the prospective Canadian Kidney Cancer Information System (CKCis) database from January 2011 to November 2015. Statistical analyses were performed using Cox regression adjusted for several risk factors and the Kaplan-Meier method.

Results

We identified 670 patients treated with sunitinib (n=577) and pazopanib (n=93). There were no significant differences in Internationa

SUBMITTER: Lalani AA 

PROVIDER: S-EPMC5434501 | biostudies-literature | 2017 Mar-Apr

REPOSITORIES: biostudies-literature